GEO-GOVERNANCE AS A TOOL FOR ANALYSIS AND GEOGRAPHICAL REFLECTION IN THE CONTEXT OF COVID-I9

Covid-19 has changed sociodemographic and eœnomic dynamics, causing a crisis that poses a great challenge for cities, spaces very affected by the pandemic. In this context, geo-governance is a useful tool to respond to new challenges, although it requires new approaches and the integration of Geographic Intelligence. This research presents a geo-governance process promoted by the City Council of Zaragoza (Spain) based on two digital citizen surveys that want to know the needs, living conditions, perception and emotional situation of citizens in the context of the pandemic. The results identify spatial patterns and allow us to reflect on the processes of citizen participation and their limitations in the context of geo-governance.. © 2021 Presses Universitaires du Mirail. All rights reserved.

Brazilian Tourists in the Context of the Covid-19 Health Crisis

In the context of a tragic health crisis due to the SARS-Cov-2 pandemic and yet to start vaccinating the population, it was noted that there was a domestic tourism flow resumed in Brazil as of September 2020. Understanding the need for people to travel in such an adverse environment has encouraged the realisation of this research with the aim of contributing to a better insight into tourism dynamics in the face of a health crisis caused by the covid-19 pandemic where the focus of the analysis is the Brazilian tourists. Accordingly, it was elaborated and applied a data collection tool on Google Forms covering the main variables to describe the profile and people attitudes who travel for leisure during the covid-19 pandemic in Brazil in the period of April 2020 to February 2021. Among the survey results, it is observed that the main motivation why respondents travelled was their "desire for rest, leisure and entertainment" seconded by the " need/desire to leave home" addressing the subjectivity of breaking with everyday life which, during a pandemic, can be even more stressful. There was a concern on coronavirus contamination but it did not prevent travel under health protection rules, particularly when choosing to travel by private or hired vehicle to natural or less urbanized environments where crowds could be avoided in a sense of security, a model close to the tourists' romantic gaze practiced by higher-income travellers.

A COMPARISON BETWEEN REAL WORLD WEIGHT LOSS OUTCOMES WITH ANTI-OBESITY MEDICATIONS BEFORE AND DURING COVID-19 PANDEMIC

Background: Obesity is a chronic and relapsing disease, with a rising prevalence and a high economic burden. Obesity is a risk factor for COVID-19 infection severity and mortality. Anti-obesity medications (AOMs) are safe and effective for weight loss. However, weight loss outcomes with AOMs during the COVID-19 pandemic are yet to be described. We hypothesized that weight loss outcomes with AOMs during COVID-19 are inferior to those before this period. Methods: We performed a systematic review of electronic medical record of patients from the Mayo Clinic Health System. We included all patients who started a long-term FDA-approved AOM (phentermine-topiramate extended release [PHEN-TOP], naltrexone-bupropion sustained release [NBSR], and liraglutide 3.0 mg). We excluded patients with a history of bariatric surgery or endoscopic procedure, those taking ≥2 AOMs, ≥3 months of prescribed AOM, and/or pregnancy. Demographic and anthropometric data were ed from in person or virtual encounters. Analysis was divided by 1) those who started an AOM at least a year before COVID-19 restrictions were set in place in the USA (i.e. first quarter of 2019 period or earlier, defined as “PreCOVID-19”), and 2) those who started an AOM during or after the first quarter of 2020, (defined as “COVID-19''). We calculated the total body weight loss percentage (TBWL%) at 3, 6, and 12 months after AOM initiation along with the percentage of patients who achieved a TBWL ³5% and ³10%, after one year of starting an AOM. Our primary endpoint was the TBWL% at 12 months. All tests were two-tailed and p-value <0.05 was considered statistically significant. Values are presented as mean ± standard deviation (SD). Results: A total of 249 patients were included in the analysis (77% female, age 48.8±12.6 years, body-mass index [BMI] 41.9±8.6 kg/m2). There were no differences in baseline characteristics between both groups (Table 1). Fifty-five percent of the patients were prescribed PHEN-TOP, 16% NBSR, and 29% liraglutide. There was a statistical difference in TBWL% between the PreCOVID-19 group compared to the COVID-19 group: 5.3±3.5% vs 4±3.7% (p=0.03) and 9.6±7% vs 6.5±5.3% (p=0.02) at 3 and 12 months, respectively (Fig. 1A). After 1 year follow-up, 53.6% of patients in the COVID-19 group achieved >5% TBWL compared with 75.3% in the PreCOVID-19 group (p=0.04), and 17.9% of patients in the COVID-19 group achieved 105% TBWL compared with 44.7% in the PreCOVID-19 group (p=0.01) (Fig. 1B). Conclusion: This study shows that weight loss outcomes to AOMs were inferior when prescribed during COVID-19 pandemic, compared to the outcomes observed prior to this. Further studies are needed to understand whether this observation is due to changes in care delivery during the pandemic or due to individual factors such as stress, decreased physical activity, remote working, among others.(Table Presented)Table 1. The demographic, antiobesity medications, and weight loss outcome distribution among patients Pre- and COVID-19.(Figure Presented) Figure 1. The weight loss outcomes of patients (Pre and COVID-19) after one year of AOM therapy (A). The distribution of patients (Pre and COVID-19) achieving >5% and >10% TBWL following one year of AOM (B).

Being first-time parents of a premature baby in times of the Covid-19 pandemic

Being a first-time parent is difficult, even more so when the baby is born immature and with extreme prematurity. The need for psychological support is evident. Objective: The first goal was to know what it means to have a premature baby in times of Covid-19 pandemic. Methods: The biographical account was used. The data analysis methodology of Amezcua and Hueso was followed after conducting two survey to the parents. Six major themes were identified: background;baby´s arrival;feelings, experiences, perceptions;influence of Covid-19 pandemic;experiences as a nurse and psychological support received. Conclusions: Nursing plays an essential role in addressing the emotions of family members due to their continuous stay with the patient. However, the emotional follow-up of family members by specialists is of particular interest, allowing them to channel emotions in times of extreme hardships.

PartiCipa Brazil: Preliminary results of differences in physical activity levels in children and adolescents with cerebral palsy

Objectives: Children and adolescents with cerebral palsy (CP) presents lower physical activity levels in comparison with typically development peers, leading to sedentary behaviours and poor endurance. Up to now, there is no information of the physical activity levels among Brazilian children and adolescents with CP and its comparison among different Gross Motor Function Classification System (GMFCS) levels. The aims of this study were to characterise levels of physical activity in Brazilian individuals with CP and analyse differences between GMFCS levels. Design: Cross-sectional study. Preliminary data from a multicentric prospective study 'Functioning curves and trajectories for children and adolescents with cerebral palsy in Brazil: PartiCipa Brazil'. Method: Parents and caregivers of 52 children and adolescents with CP (mean age 7.5±3.5) participated in an online interview. Participants filled out an online form that included the GMFCS Family Report and the 4-item Early Activity Scale for Endurance (EASE) for children and adolescents. The interview was conducted by a trained physical therapist. One-way analysis of variance (ANOVA) was used to identify differences among physical activity levels according to the EASE in the five different GMFCS levels, considering an alpha = 0.05 as statistically significant. This study was approved by the ethics committee (CAAE: 28540620.6.1001.5133). Results: Of the 52 participants, 17.3% were classified as GMFCS level I, 30.8% level II, 11.5% level III, 15.4% level IV, and 25.0% level V. Overall Brazilian participants' EASE mean scores were 2.92 ±1.96. EASE mean scores by each GMFCS levels were 4.13±0.70 for GMFCS level I, 2.98±0.91 level II, 3.16±0.70 level III, 2.68±1.0 level IV, and 2.92±1.06 level V. There were statistically significant differences on physical activity levels among the GMFCS groups (p > 0.01). Post-hoc analysis via Tukey test, indicated that these differences were between individuals GMFCS level I and levels IV (p > 0.01). No other statistically significant differences among the remaining GMFCS levels were found. Conclusion: Overall, Brazilian children and adolescents with CP present low levels of physical activity, with differences seen amongst the GMFCS levels. The main differences were presented between those children and adolescents with higher mobility levels and those with more restricted mobility. The presented results might be influenced by COVID-19 related social isolation. Further data will confirm this results and present physical activity curves of Brazilian children and adolescents with CP.

Tourism in Aracaju/SE in times of COVID-19: threats and trends

This article assumes that international tourism is facing a deep crisis as a result of the COVID-19 pandemic that brought about the paralysis of the sector, resulting in trillions of losses. However, its effects occur unevenly in space-time, which requires localized studies to decipher the specificities of its impacts on tourism in different places. Therefore, this study aims to analyze the implications on tourism, specifically, on tourism services in the city of Aracaju/SE, from the restrictive measures instituted with the pandemic. The methodological procedures adopted in this exploratory research were the bibliographic survey, the documental research, as well as interviews with public agents and application of forms with city residents, with a quantitative-qualitative analysis approach. The results point to new challenges for the destination with regard to the resumption and attraction of tourist flows. In this sense, it is urgent to prepare creative proposals and protocols adjusted in the world scenario for the reactivation of the sector's activities.

The digital gap in Spanish households: Sociodemographic factors that explain the availability of ITC in times of the COVID-19 global pandemic

Due to the global COVID-19 pandemic, the government of Spain declared the State of Alarm in March 2020. One of its consequences has been the increase in remote working and online teaching-learning processes. Taking homes as unit of analysis, the data given by the Survey on Equipment and Use of Information and Communication Technologies in Households conducted by the Spanish National Institute of Statistics is analysed. Two different analyses were undertaken: A descriptive analysis on the variable possession of a computer and internet broadband (constructed from those offered by the aforementioned survey) and a logistic regression analysis on sociodemographic factors that explain the availability of ICT. The results indicate that the household model is the principal variable to explain the digital gap more accurately than other factors such as economic aspects or educational levels of those responsible for the household. © 2022, Fundacion Sistema. All rights reserved.

DIGITAL MARKETING IN CRISIS TIME

The crisis can affect an organization for many reasons, including changes that occur in the market, technology, competition or even a pandemic currently experienced. With this, it is necessary to find solutions so that it is possible to work around the situation and continue operating in the market. This article aims to analyze what are the digital marketing strategies adopted by organizations in different crisis situations, including the Covid-19 pandemic. For this purpose, an integrative review of articles published in the Web of Science, Scopus, SPELL and SciELO databases was carried out. The results show that several strategies in the digital environment are capable of collaborating with the challenges that organizations face with globalization, such as investing in their websites, acting on their social media with content and campaigns, applications, virtual assistants, advertising and others. A research framework was created with the aim of synthesizing the findings of this integrative review. Organizations from different sectors can mirror these strategies to deal with the crisis they face or even join them so that they are not hit by unexpected adversities, resulting in loss of space or even their withdrawal from the market.

COVID-19 infection impact on cardiovascular and thrombotic events during acute phase and medium-term of the disease

Background: Coronavirus disease (COVID-19) was labelled a global pandemic in April 2020 by the World Health Organisation. By December of the same year the disease caused by SARS-COV-2, known as COVID-19 (Coronavirus disease 2019), had spread over 200 countries, infecting more than 70 million people, causing more that 1.5 million of deaths. Recent studies suggest SARS-CoV-2 infection may be related to cardiovascular and thrombotic events although the strength of association remains unclear. Aims: Evaluate the emergence of cardiovascular and thrombotic events (such as major acute cardiovascular events, ictus and other thrombosis) in the acute moment and in medium-term follow-up in COVID-19 patients. Methods: Single-Center, retrospective, observational study of cohorts based on all the inhabitants of the health area. Survival analysis of main outcomes (mortality, heart failure [HF], and major acute cardiovascular events-MACE -[a composite of cardiovascular mortality, myocardial infarction and stroke]) were adjusted by multivariate logistic regression. Results: Of the total population studied, 447,979 inhabitants, 1,030 (0.23%) were diagnosed with COVID-19 infection, of which 14,8% were smokers, 31,2% had high blood pressure (HTA), 12,8% had diabetes, 29,2% had dyslipidaemia, 2,7% had peripheral artery disease, 4,7% had ischemic heart disease, 3,3% had had a previous transient ischemic attack, 10% were in anti-aggregation treatment and 5,8% were in anticoagulation treatment at the time of diagnosis. Concerning the analytics middle values, the group treated with ACEI/ARAB had higher troponins and ferritin than the group without ACEI/ARAB treatment, whereas higher reactive C protein and D-dimer were found in this last group. The main results showed that COVID-19 infection had no effect regarding to cardiovascular and thrombotic disease on mortality (OR: 1.64, 95% CI 0.98 2.76, p=0.062), heart failure (OR: 0.98, 95% CI 0.53 1.79, p=0.942), thrombotic events (OR: 1.02, 95% CI 0.22 4.83, p=0.98) and major acute cardiovascular events (OR: 0.88, 95% CI 0.48 1.60, p=0.665). Conclusions: In conclusion, COVID-19 infection had no effect on the emergence of cardiovascular or thrombotic events taking into account the 6-month prognosis, defined as mortality, heart failure, or major acute cardiovascular events.

Prognostic impact of treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the acute phase and medium-term on COVID-19 infected patients

Introduction: The first case of COVID-19 infection was described in Wuhan, China, in December 20191. Shortly after, cases of limited humanto-human transmission were reported in other countries, which made the WHO declare the outbreak a Public Health Emergency of International Concern (ESPII) on January 30, 20202. Recent studies suggest that treatment with angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARAB) during acute COVID-19 infection has no effect on mortality3, but it is no evidence regarding the medium-term clinical implication of previous treatment with ACEI/ARAB on the prognosis of patients with COVID-19 infection. Purpose: The aim of this study is to evaluate the clinical implication of the use of ACEI/ARB in the acute moment and in medium-term follow-up in patients after COVID-19. Methods: It is a single-centre, retrospective, analytical observational study of cohorts based on all consecutive patients diagnosed with COVID-19 who were admitted during the first wave (March 10th until May 31st), of the pandemic in our health area. Survival analysis of main outcomes (mortality, heart failure, and major acute cardiovascular events [a composite of cardiovascular mortality, myocardial infarction and stroke]) were adjusted by multivariate logistic regression. Results: Of the total population studied, 447,979 inhabitants, 1,030 (0.23%) were diagnosed with COVID-19 infection, of which 196 (19%) were under treatment with ACEI/ARB at the time of diagnosis. The main results showed that ACEI/ARB treatment (combined and individually) had no effect on mortality (Hazard Ratio [HR]: 1.64, 95% Confidence Interval [CI] 0.98 2.76, p=0.062), heart failure (HR: 0.98, 95% CI 0.53 1.79, p=0.942), thrombotic events (HR: 1.02, 95% CI 0.22 4.83, p=0.98) and major acute cardiovascular events (HR: 0.88, 95% CI 0.48 1.60, p=0.665). Conclusions: In conclusion, previous treatment with ACEI/ARB in patients with COVID-19 had no effect on the 6-month prognosis, defined as mortality, heart failure, or major acute cardiovascular events. Withdrawal of ACEI/ARB in patients testing positive for COVID-19 would not be justified, in line with current recommendations of scientific societies and government agencies.

Gross Motor Function Parent Report (GMF-PR): Preliminary evidence of validity

Background and Objective(s): The need for family-centered measures that reflect children's abilities in their natural environments has come to forefront, accentuated by the recent shift to remote assessment necessitated by the COVID pandemic. This study describes the first steps in the validation of a new instrument, the Gross Motor Function Parent Report (GMF-PR), a parent-completed, modified 30-item version of the Gross Motor Function Measure to report gross motor function of children and youth with cerebral palsy in their home and community environments. Study Design: Measurement Study. Study Participants & Setting: Assessment records of 50 children and adolescents with CP, aged 1 year to 19 years, were used for this analysis. Gross motor abilities were classified using the Gross Motor Function Classification System (GMFCS). Materials/Methods: This study was approved by the Ethics Committee of Universidade Federal de Juiz de Fora. Gross Motor Function Measure (GMFM-66) scores were accessed from an existing data bank. GMF-PR scores were determined using related items in the GMFM assessments. Correlation coefficients were calculated using: (1) GMFM-66 and GMF-PR scores and, (2) GMF-PR scores and GMFCS levels. Intraclass correlation coefficients (ICC) were used to estimate inter-measure score agreement. Discriminative validity was evaluate using a one-way ANOVA and Tukey's pairwise comparisons to compare scores between the GMFCS levels (alpha=0.05). Results: Data were available from 50 children and adolescents (8.0 ± 4.2y), equally divided between levels I-V of the GMFCS. Pearson correlation showed a positive and strong association between GMFM-66 and GMF-PR scores (r=0.97, p<0.001). Spearman-rho showed an inverse and strong association between GMF-PR and GMFCS (rho=-0.91, p<0.001). There was excellent agreement between GMFM-66 and GMF-PR scores (ICC=0.93;0.88≥CI95%≥0.96). Lastly, analysis of variance showed a significant difference of GMF-PR scores among levels of GMFCS (p<0.001), demonstrating discriminative validity. Conclusions/Significance: These preliminary results on the validation of the GMF-PR show promising evidence for future use of this new measure. Work is underway to further explore discriminant validity of the measure. With continued evidence from the validation process, this instrument may be a useful tool for the evaluation of the motor functioning of children and adolescents with cerebral palsy in different contexts.

Standard Radiotherapy Fractionation Toxicity Versus Ultra-Hypofractionation In Breast Cancer

Purpose or Objective Radiotherapy is an essential treatment in the local control of breast cancer. Standard treatment is currently carried out in 15 daily sessions. At present, following the results of the phase III Fast-Foward trial and in view of the situation triggered by COVID-19, the number of sessions has been reduced to 5. The RHEMA (extreme hypofractionated radiotherapy in breast cancer) study has been initiated in Spain. It is a multi-hospital study designed to determine the evolution of the change in fractionation. The hypothesis is that the change in fractionation does not increase acute toxicity. The aim of the study was to determine whether there are differences in acute skin toxicity in breast cancer patients who receive adjuvant radiotherapy according to the different fractionation schedules applied. Materials and Methods We retrospectively analysed skin toxicity in patients treated with glandular radiotherapy at the end of treatment and one month later. Out of 75 patients treated with the ultra-hypofractionated schedule, 58 patients with a follow-up of more than 1 month were compared with 38 patients who received the standard schedule, all of whom were treated in 2020 in the Multihospital Clinical Unit of Radiation Oncology of Aragon. In the case of the ultra-hypofractionated treatment, as indicated in the GEORM (Spanish group of breast radiation oncology) guidelines at the beginning of the pandemic, was carried out in 5 sessions with a total dose of 26 Gy over the breast and 29 Gy over the tumour bed, while the standard treatment, consisted in 15 sessions with a total dose of 40.5 Gy over the breast and 48 Gy over the tumour bed. Results The median age was 61 years in the standard group and 63.4 years in the ultra-hypofractionated group. No significant differences were observed in the histological profile. Differences were found in toxicity at the end of treatment, being significantly higher in the standard group (p 0.03). On the other hand, no differences were found in toxicity one month after the end of treatment. Grade 2 toxicity appeared in 2 patients from the ultra-hypofractionated group and 4 from the standard group, with no significant difference (p 0.943). There were no differences in the development of grade 1 toxicity and no grade 3 or higher toxicity was observed. Conclusion It can be concluded that the use of the ultra-hypofractionation schedule compared to standard treatment was not associated with an increase in acute skin toxicity in our series. This is a change in fractionation that could be adopted as a routine treatment in radiation oncology departments after verifying the results with a larger number of patients and a longer follow-up.

Side effects of the BNT162b2 vaccine in the personnel of the Military Central Hospital.

OBJECTIVE: The pandemic disease by SARS-CoV-2 infection does not have an effective treatment. To prevent the disease, scientists developed vaccines that the clinicians use as an emergency licensed vaccine. The objective of this study was to determine the side effects in personnel vaccinated at the Military Central Hospital of Mexico with the BNT162b2 vaccine. PATIENTS AND METHODS: This study included the subjects who had received both doses of the BNT162b2 vaccine between December 2020 and February 2021. We asked about the side effects after the first and the second vaccine doses. One group had no history of COVID-19, and the second had a history of COVID-19. ANTI-SARS-CoV-2 antibodies were measured by the immunodetection technique in the second group only. RESULTS: We included 946 participants, 62% were women, and 80% were without comorbidities; 680 were included in the first group, and only 266 were in the second group. After the first dose, 77% of the first group and 86% of the second group presented some side effects. After the second dose, 84% of the first group and 89% of the second group showed some side effects. The main side effect was mild pain. All participants (126) were IgG positive, and only 26.9% were IgM positive at 17.5 days (12.8 days, 20.3 days) after the second dose. CONCLUSIONS: There is a positive correlation between side effects after the first dose in patients with a history of previous SARS-CoV-2 infection compared to those who did not. Nevertheless, this correlation is not present after the second dose. The low percentage of IgM could be related to the time interval between vaccination and sample measure.

ALBUMIN LEVELS HAVE STRONGASSOCIATION WITH MORTALITY IN COVID-19 INFECTED PATIENS

Introduction: To optimize hospital management of COVID-19 patients it is important to have parameters that allow us to identify patient with an increased risk of death. Although hypoalbuminemia has been related with severity in COVID-19, there is no agreement of the albumin cutoff points with a potential clinical use. Additionally, a measure of strength of the association between albumin levels and mortality has not been reported. Therefore, the aim of this study is to evaluate if Child Pug albumin categories are associated with mortality and obtain the strength of the association. Methods: Patients admitted to hospitalization with a positive SARS CoV 2 PCR from 4 April to 24 June 2020 were analyzed. Three groups were formed based on Child-Pugh albumin categories. Death frequency were compared between groups and statistical significance of the difference were assessed using a Xi2 test, strength of association between albumin levels and death was evaluated with a Kendall´s Tau B test. Results: A total of 348 patients were studied, age was 54.4 ± 14.7 years, 250 (71.8%) were male and 182 patients died (52%). Association of Albumin level and Death is presented Table 1, Kendall Tau B shows that knowing albumin level improves in 32% the prediction of death and since it has a negative coefficient at a lower level of albumin, risk of death increase. Conclusions: Kendall´s Tau-B shows a strong association between Child-Pug albumin categories and death, so is possible it´s use in clinical decisions as a marker of severity.

Analysis of outcomes of emergency general and gastrointestinal surgery during the COVID-19 pandemic.

BACKGROUND: Few surgical studies have provided adjusted comparative postoperative outcome data among contemporary patients with and without COVID-19 infection and patients treated before the pandemic. The aim of this study was to determine the impact of performing emergency surgery in patients with concomitant COVID-19 infection. METHODS: Patients who underwent emergency general and gastrointestinal surgery from March to June 2020, and from March to June 2019 in 25 Spanish hospitals were included in a retrospective study (COVID-CIR). The main outcome was 30-day mortality. Secondary outcomes included postoperative complications and failure to rescue (mortality among patients who developed complications). Propensity score-matched comparisons were performed between patients who were positive and those who were negative for COVID-19; and between COVID-19-negative cohorts before and during the pandemic. RESULTS: Some 5307 patients were included in the study (183 COVID-19-positive and 2132 COVID-19-negative during pandemic; 2992 treated before pandemic). During the pandemic, patients with COVID-19 infection had greater 30-day mortality than those without (12.6 versus 4.6 per cent), but this difference was not statistically significant after propensity score matching (odds ratio (OR) 1.58, 95 per cent c.i. 0.88 to 2.74). Those positive for COVID-19 had more complications (41.5 versus 23.9 per cent; OR 1.61, 1.11 to 2.33) and a higher likelihood of failure to rescue (30.3 versus 19.3 per cent; OR 1.10, 0.57 to 2.12). Patients who were negative for COVID-19 during the pandemic had similar rates of 30-day mortality (4.6 versus 3.2 per cent; OR 1.35, 0.98 to 1.86) and complications (23.9 versus 25.2 per cent; OR 0.89, 0.77 to 1.02), but a greater likelihood of failure to rescue (19.3 versus 12.9 per cent; OR 1.56, 95 per cent 1.10 to 2.19) than prepandemic controls. CONCLUSION: Patients with COVID-19 infection undergoing emergency general and gastrointestinal surgery had worse postoperative outcomes than contemporary patients without COVID-19. COVID-19-negative patients operated on during the COVID-19 pandemic had a likelihood of greater failure-to-rescue than prepandemic controls.

Lung uptake detected by68ga-psma-11 pet/ct in prostate cancer patients with sars-cov-2: A case series

Coronavirus disease 2019 (COVID-19) pathology is associated with neoangiogenesis and interstitial pneumonia.68Ga-PSMA-11-PET/CT is able to image in vivo PSMA (Prostate-Specific Membrane Antigen) expression on both prostate cancer (PCa) cells and neovasculature endothelial cells. The aim of the case series was to explore pulmonary PSMA expression not related to cancer in patients with PCa and concomitant COVID-19. In this retrospective, multicenter case series, patients who underwent68Ga-PSMA-11-PET/CT for PCa and concomitant proven COVID-19 infection were analyzed. Patients were stratified according to68Ga-PSMA-11 intensity of uptake in the lung (SUVmax). Low uptake: < blood pool;mild-to-moderate uptake: > blood pool and < liver;intense uptake: > liver. Potential correlation between pulmonary68Ga-PSMA-11 uptake not related to PCa and CT patterns typical for COVID-19 was assessed. Nine patients were included, all of them presenting abnormal68Ga-PSMA-11 uptake, at different grades: 2/9 low, 6/9 mild-to-moderate, 1/9 high. Uptake distribution was generally bilateral, peripheral and posterior, positively matching with ground-glass CT alterations in 7/9 (78%) patients, while mismatch was observed in 2/9 (22%). 1/9 patients presented PCa lung metastases at68Ga-PSMA-11.68Ga-PSMA-11-PET/CT detected increased PSMA uptake within the lung, not related to PCa, matching with CT typical COVID-19 patterns in almost all patients. Further studies are needed to evaluate the role of68Ga-PSMA-11 PET in COVID-19 patients and the potential role of PSMA overexpression as a biomarker for neoangiogenesis, in both oncological and infective disorders.